[Coating Technology for Flow Diverter Devices].

Area of Science:

• Biomaterials Science
• Medical Device Engineering
• Vascular Surgery

Background:

• Flow diverter (FD) devices are standard for cerebral aneurysms, redirecting flow to prevent rupture.
• Current FD treatment necessitates dual antiplatelet therapy (DAPT), increasing bleeding risks.
• Reducing DAPT necessity is crucial for broader FD application, especially in ruptured aneurysms.

Purpose of the Study:

• To review the potential of 2-methacryloyloxyethyl phosphorylcholine (MPC) polymers in enhancing FD biocompatibility.
• To explore how MPC polymer coatings can mitigate thromboembolic risks associated with FDs.
• To assess the long-term goal of enabling single antiplatelet therapy for FD treatments.

Main Methods:

• Review of existing literature on FD technology and antiplatelet therapies.
• Analysis of interfacial properties and hemocompatibility of MPC polymers.
• Examination of MPC polymer integration into FD devices for improved biological response.

Main Results:

• FDs effectively reduce intra-aneurysmal pressure and promote healing but carry thromboembolic risks.
• MPC polymers, mimicking cell membrane phospholipids, exhibit excellent hemocompatibility.
• MPC coatings show promise in suppressing coagulation and improving endothelialization on medical devices.

Conclusions:

• MPC polymer coatings represent a promising strategy to enhance FD biocompatibility.
• This innovation could lead to reduced reliance on DAPT, minimizing hemorrhagic risks.
• The development aims to expand FD use to a wider patient population, including those with ruptured aneurysms.